Bleichroeder LP’s Structure Therapeutics GPCR Stock Holding History

Bleichroeder LP’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$696K	–	83
2025 Q4	$696K	Sell	10,000 -10,000	-50%	-$408K	0.12%	39
2025 Q3	$560K	Buy	20,000 +10,000	+100%	+$199K	0.11%	46
2025 Q2	$207K	Hold	10,000	–	–	0.05%	53
2025 Q1	$173K	Hold	10,000	–	–	0.05%	58
2024 Q4	$271K	Hold	10,000	–	–	0.07%	49
2024 Q3	$439K	Hold	10,000	–	–	0.12%	40
2024 Q2	$393K	Buy	10,000 +5,000	+100%	+$205K	0.12%	42
2024 Q1	$214K	Hold	5,000	–	–	0.05%	50
2023 Q4	$204K	Buy	+5,000	New	+$287K	0.05%	46

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bleichroeder LP's GPCR Position: Q1 2026 in Review

Bleichroeder LP sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 10,000 shares — an estimated $696K sold.

Bleichroeder LP first reported a position in GPCR in Q4 2023 and held it in 9 quarters. The position peaked at $696K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Bleichroeder LP reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Bleichroeder LP sold 10,000 Structure Therapeutics shares in Q1 2026, an estimated $696K.
Bleichroeder LP first reported a position in Structure Therapeutics in Q4 2023 and held it in 9 quarters.
Bleichroeder LP's Structure Therapeutics position peaked at $696K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Bleichroeder LP's 13F filing for Q1 2026, filed 14 May 2026.